Table 1. Demographic and clinical... | Rockefeller University Press

Table 1.

Demographic and clinical characteristics, and hematological and clinical biochemistry findings of COVID-19 patients

Patient no.	1	2	3	4
Gender	M	F	M	M
Age (yr)	56	63	51	73
Known comorbidities	Emphysema, extrinsic asthma	Type 2 diabetes, obesity, hyperanxiety, epilepsy	Type 2 diabetes, hypertension, fatty liver	None
Chronic treatments	Inhaled CS and β2 agonists, leukotriene receptor antagonists, SSRI	Anti-diabetes (metformin), neuroleptic (haloperidol), anxiolytic (prothipendyl), anti-epileptic (sodium valproate), L-thyroxin, anti-convulsive (procyclidin)	Anti-diabetes (metformin, empagliflozine), anti-hypertensive (ACE inhibitor, angiotensin 2 receptor antagonist), α1 receptor antagonists	L-thyroxin, aspirin
Time from admission to death (d)	18	8	32	22
Symptom duration before admission (d)	8	7	7	2
Duration of ventilator management (d)	15	8	32	22
Secondary lung infection	No	No	Yes	Yes
Secondary disorder	Renal failure	Pneumothorax	Renal failure, hypercortisolemia	Renal failure, atrial fibrillation
In-hospital antiviral therapy (hydroxychloroquine)	Yes	Yes	Yes	Yes
In-hospital antibiotic therapy	Yes	Yes	Yes	Yes
In-hospital antifungal therapy	No	No	Yes	No
In-hospital anticoagulant therapy (heparin)	Yes	No	No	No
Cause of death	ARDS, multi-organ failure	Pneumonia	ARDS	ARDS
Diffuse alveolar damage	Yes	Yes	Yes	Yes
Lymphocytes [1.1–4.5 10³/μl]	1.41	0.17^a	0.97^a	Below detection^a
Neutrophils [1.5–4.5 10³/μl]	25.84^b	8.7^b	6.93^b	18.35^b
Monocytes [0.1–0.9 10³/μl]	1.61^b	0.34	0.75	Below detection^a
Platelets [150–370 10³/µl]	7^a	217	70^a	26^a
CRP [0–5 µg/ml]	391.4^b	286.8^b	183.3^b	231^b
Fibrinogen [1.79–3.86 mg/ml]	4.43^b	7.55^b	3.47	5.70^b
IL-6 [< 1 IU/ml]	Not measured	384.8^b	129.3^b	1,077.3^b
D-dimer [< 500 µg/liter]	2,106^b	7,440^b	9,149^b	4,559^b

Patient no.	1	2	3	4
Gender	M	F	M	M
Age (yr)	56	63	51	73
Known comorbidities	Emphysema, extrinsic asthma	Type 2 diabetes, obesity, hyperanxiety, epilepsy	Type 2 diabetes, hypertension, fatty liver	None
Chronic treatments	Inhaled CS and β2 agonists, leukotriene receptor antagonists, SSRI	Anti-diabetes (metformin), neuroleptic (haloperidol), anxiolytic (prothipendyl), anti-epileptic (sodium valproate), L-thyroxin, anti-convulsive (procyclidin)	Anti-diabetes (metformin, empagliflozine), anti-hypertensive (ACE inhibitor, angiotensin 2 receptor antagonist), α1 receptor antagonists	L-thyroxin, aspirin
Time from admission to death (d)	18	8	32	22
Symptom duration before admission (d)	8	7	7	2
Duration of ventilator management (d)	15	8	32	22
Secondary lung infection	No	No	Yes	Yes
Secondary disorder	Renal failure	Pneumothorax	Renal failure, hypercortisolemia	Renal failure, atrial fibrillation
In-hospital antiviral therapy (hydroxychloroquine)	Yes	Yes	Yes	Yes
In-hospital antibiotic therapy	Yes	Yes	Yes	Yes
In-hospital antifungal therapy	No	No	Yes	No
In-hospital anticoagulant therapy (heparin)	Yes	No	No	No
Cause of death	ARDS, multi-organ failure	Pneumonia	ARDS	ARDS
Diffuse alveolar damage	Yes	Yes	Yes	Yes
Lymphocytes [1.1–4.5 10³/μl]	1.41	0.17a	0.97a	Below detectiona
Neutrophils [1.5–4.5 10³/μl]	25.84b	8.7b	6.93b	18.35b
Monocytes [0.1–0.9 10³/μl]	1.61b	0.34	0.75	Below detectiona
Platelets [150–370 10³/µl]	7a	217	70a	26a
CRP [0–5 µg/ml]	391.4b	286.8b	183.3b	231b
Fibrinogen [1.79–3.86 mg/ml]	4.43b	7.55b	3.47	5.70b
IL-6 [< 1 IU/ml]	Not measured	384.8b	129.3b	1,077.3b
D-dimer [< 500 µg/liter]	2,106b	7,440b	9,149b	4,559b

For hematological and clinical biochemistry values, references ranges are indicated in brackets. ACE, angiotensin-converting enzyme; CRP, C-reactive protein; CS, corticosteroids; F, female; M, male; SSRI, selective serotonin reuptake inhibitor.

Values below the reference range.

Values above the reference range.

[ViewLarge]

Sharing Unavailable